Cargando…
The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure
OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315566/ https://www.ncbi.nlm.nih.gov/pubmed/25670892 http://dx.doi.org/10.2147/CIA.S77417 |
_version_ | 1782355497106538496 |
---|---|
author | Fu, Shihui Xie, Leixing Li, Dongyun Ye, Ping Luo, Leiming |
author_facet | Fu, Shihui Xie, Leixing Li, Dongyun Ye, Ping Luo, Leiming |
author_sort | Fu, Shihui |
collection | PubMed |
description | OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with patient characteristics, and screen for decisive factors of NT-proBNP in Chinese elderly with chronic heart failure (CHF). PATIENTS AND METHODS: There were 306 patients (≥60 years) with CHF chosen as study subjects. Each one received an assessment of NT-proBNP on serum. The end point was all-cause mortality during a mean follow-up period of 471 days. RESULTS: Subjects had a median age of 85 (60–100) years, a median NT-proBNP of 1,743.4 pg/mL, and a median SHFS of 1.87. During the follow-up period, 104 deaths occurred. NT-proBNP was significantly related to mortality (odds ratio 1.603, 95% confidence interval 1.407–1.826; P<0.001) and the significance persisted after full adjustment (odds ratio 1.282, 95% confidence interval 1.103–1.489; P=0.001). Age, New York Heart Association class IV CHF, plasma albumin, and neutrophils/lymphocytes were also independent predictors for mortality (P<0.05 for all). NT-proBNP and the SHFS showed similar predictive capacities (0.736 versus 0.796, P=0.105). The addition of NT-proBNP to the SHFS (0.818 versus 0.796, P=0.168) generated marginal growth in the c-statistic. The model based on NT-proBNP consisting of all selected predictors in this study, including age, New York Heart Association class IV CHF, plasma albumin, neutrophils/lymphocytes, and NT-proBNP, had a moderately higher c-statistic compared with the SHFS (0.846 versus 0.796, P=0.066). NT-proBNP was bound with the SHFS (r=0.500, P<0.001). Characteristics regarding general condition, inflammation, and cardiac and renal function were the decisive factors of NT-proBNP (P<0.05 for all). CONCLUSION: As a comprehensive representation of the patient characteristics described earlier, NT-proBNP values provided significant prognostic power similar to the SHFS in Chinese elderly with CHF. A novel model based on NT-proBNP could offer help for risk stratification. |
format | Online Article Text |
id | pubmed-4315566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43155662015-02-10 The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure Fu, Shihui Xie, Leixing Li, Dongyun Ye, Ping Luo, Leiming Clin Interv Aging Original Research OBJECTIVE: This study was conducted to research the prognostic utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP), compare the utility of the Seattle Heart Failure Score (SHFS) with NT-proBNP, develop a risk-evaluation model based on NT-proBNP, assess the associations of NT-proBNP with patient characteristics, and screen for decisive factors of NT-proBNP in Chinese elderly with chronic heart failure (CHF). PATIENTS AND METHODS: There were 306 patients (≥60 years) with CHF chosen as study subjects. Each one received an assessment of NT-proBNP on serum. The end point was all-cause mortality during a mean follow-up period of 471 days. RESULTS: Subjects had a median age of 85 (60–100) years, a median NT-proBNP of 1,743.4 pg/mL, and a median SHFS of 1.87. During the follow-up period, 104 deaths occurred. NT-proBNP was significantly related to mortality (odds ratio 1.603, 95% confidence interval 1.407–1.826; P<0.001) and the significance persisted after full adjustment (odds ratio 1.282, 95% confidence interval 1.103–1.489; P=0.001). Age, New York Heart Association class IV CHF, plasma albumin, and neutrophils/lymphocytes were also independent predictors for mortality (P<0.05 for all). NT-proBNP and the SHFS showed similar predictive capacities (0.736 versus 0.796, P=0.105). The addition of NT-proBNP to the SHFS (0.818 versus 0.796, P=0.168) generated marginal growth in the c-statistic. The model based on NT-proBNP consisting of all selected predictors in this study, including age, New York Heart Association class IV CHF, plasma albumin, neutrophils/lymphocytes, and NT-proBNP, had a moderately higher c-statistic compared with the SHFS (0.846 versus 0.796, P=0.066). NT-proBNP was bound with the SHFS (r=0.500, P<0.001). Characteristics regarding general condition, inflammation, and cardiac and renal function were the decisive factors of NT-proBNP (P<0.05 for all). CONCLUSION: As a comprehensive representation of the patient characteristics described earlier, NT-proBNP values provided significant prognostic power similar to the SHFS in Chinese elderly with CHF. A novel model based on NT-proBNP could offer help for risk stratification. Dove Medical Press 2015-01-27 /pmc/articles/PMC4315566/ /pubmed/25670892 http://dx.doi.org/10.2147/CIA.S77417 Text en © 2015 Fu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Fu, Shihui Xie, Leixing Li, Dongyun Ye, Ping Luo, Leiming The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title_full | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title_fullStr | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title_full_unstemmed | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title_short | The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure |
title_sort | predictive capacity and additional prognostic power of n-terminal pro-b-type natriuretic peptide in chinese elderly with chronic heart failure |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315566/ https://www.ncbi.nlm.nih.gov/pubmed/25670892 http://dx.doi.org/10.2147/CIA.S77417 |
work_keys_str_mv | AT fushihui thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT xieleixing thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT lidongyun thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT yeping thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT luoleiming thepredictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT fushihui predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT xieleixing predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT lidongyun predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT yeping predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure AT luoleiming predictivecapacityandadditionalprognosticpowerofnterminalprobtypenatriureticpeptideinchineseelderlywithchronicheartfailure |